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OBJECTIVES: Imatinib is considered standard of care for 1st line treatment of
chronic myeloid leukemia (CML) in Brazil. Long-term treatment effectiveness,
however, is jeopardized by questionable adherence among patients receiving
imatinib. The goal of this study is to document the adherence of CML patients to
imatinib and the impact of these adherence levels on long-term prognosis.
METHODS: A longitudinal cohort analysis was performed using SIA/DATASUS
data from January 2008 through Jun 2010. Inclusion criteria included patients 
18 years old; diagnosed with CML (ICD10 92.1) in Chronic Phase; beginning 1st
line treatment with imatinib from January 1, 2008 to December 31, 2008; and a
minimum follow-up period of 6 months. Adherence of all patients that met
inclusion criteria was calculated based on medication possession ratio (MPR)
over a 15-month period. Patients were categorized as adherent (MPR  0.9) or
non-adherent (MPR  0.9). Using uni and multivariate logistic regression we
analyzed the following covariates: adherence, age, gender, region of country
and other comorbidities for their influence on progression rates. RESULTS: In
total, 386 patients, 56% males and mean (SD) age 48 (15) years, were included in
the study. There were 210 (54%) patients calculated as being adherent (MPR 
0.9). At the end of the 24-months of follow-up, 20% patients from the non-
adherent group had progressed, versus 10% in the adherent group (log-rank
p0,02). Patients from North, South and Southeast regions of Brazil had signif-
icantly higher adherence as compared with those from Northeast or Center-
west. According to the multivariate logistic regression, lower adherence is sig-
nificantly associated with higher progression rates. CONCLUSIONS: Adherence
to imatinib is associated with a better progression-free survival profile, with
statistical significance being observed after a 24-months period. Non-adherence
was observed in 46% of the population studied.
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OBJECTIVES: Given that treatments for advanced breast cancer are palliative
rather than curative, the patient-perceived impact of chemotherapy is a critical
outcome. To date, no studies have estimated the strength of patient preferences for
a comprehensive set of toxicities associated with breast cancer treatments. The
objective of this study was to measure patient preferences for treatment-related
toxicities in advanced breast cancer. METHODS: This was a cross-sectional Web-
based survey of women with stage I through IV breast cancer who were recruited
through web forums and newspaper ads. Using the standard gamble approach,
each participant valued her own current health state in the absence of side effects
and nine health states describing that current health state plus each of nine grade
III/IV toxicities. Toxicity disutilities were calculated by subtracting the utility for
current health from that for current health plus the toxicity. RESULTS: Of the 103
patients who completed the web survey, 21 had to be excluded given irrational
responses. The mean ‘current health’ utility for the sample was 0.837. Patients
assigned higher utilities to their current health state than to the toxicity states.
Alopecia received the highest utility (mean0.79; disutility  4.6) of all the side
effects, and diarrhea received the lowest (mean0.69; disutility  14.7). Patterns
were similar across disease stages, although patients with more advanced disease
(stage III or IV) generally assigned lower utilities (greater disutilities) to the various
toxicities. For several side effects (alopecia, nausea, vomiting, fatigue, mucositis,
and diarrhea), patients who had experience with the side effect reported higher
utility values compared to those who had not experienced the side effect.
CONCLUSIONS: To our knowledge, this study was the first to report strength of
preferences for toxicities associated with advanced breast cancer treatments. The
utilities obtained in this studymay be used in future cost-effectiveness evaluations
of breast cancer therapies.
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OBJECTIVES: Peoples’ beliefs towards health and illness play an important role in
health seeking behavior. Cancer patients’ beliefs regarding cancer have been re-
ported to be important factors affecting screening and treatment seeking behavior.
This study was aimed to evaluate cancer patients’ beliefs about cancer and its
causes. METHODS: A qualitative research approach was adapted. After obtaining
institutional ethical approval, patients with different types and stages of cancer
from the three major ethnic groups in Malaysia were purposively selected to par-
ticipate in the interview. Twenty patients whom had consented were interviewed
using a semi-structured interview guide. After conducting 18 interviews the satu-
ration point was reached and nomore themes were emerged from the subsequent
interviews. All interviews were audiotaped, transcribed verbatim and translated
into English for thematic content analysis. RESULTS: The emergent themes were
as follows: unknown reasons, internal factors, environmental perceptions, and
spiritual attributions. In this preliminary investigation cancer patients described
cancer as a disease present in every human being and itmay become visible during
the course of life. Genetic predisposition, female gender and hematological factors
were reported to be some of the internal factors. Unhealthy life style habits such as
smoking, high consumption of red meat, and pesticides in foods were some of the
environmental factors that were described. Among those who claimed to have
healthy habits prior to the illness, there was a rejection of the notion that un-
healthy life style was a cause. A strong spiritual connection was found as many
patients described their cancer diagnosis as ‘God’s will.’ CONCLUSIONS: This ex-
ploratory investigation suggests that cancer patients’ understanding about cancer
is complex in nature. The findings may help health care providers remove myths
about cancer and reassure patients during the treatment decisionmaking process.
It may also help in improving patients’ compliance towards the proven cancer
therapies.
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OBJECTIVES: To assess patients’ knowledge of chronic myeloid leukemia (CML)
treatment response categorizations and to evaluate health-related quality-of-life
(HRQOL) outcomes and treatment satisfaction among CML patients achieving dif-
ferent levels of responses. METHODS: CML patients were invited to complete an
on-line survey that assessed their knowledge of different CML treatment-response
categorizations. Data on HRQOL outcomes and treatment satisfaction were also
collected. Chi-square and Fisher’s test were used for statistical comparisons.
RESULTS: 123 patients obtained through the ACOR database completed the survey.
The mean age of respondents was 63 years, 48.8% were male, and 95.9% had some
level of college experience. Over 90% were familiar with the different levels of CML
treatment responses, with 96.8% self-reporting a current hematologic response,
70.7% a current cytogenetic response, and 68.3% a molecular response. However,
71.5% felt CML patients needmore information on the types of responses, with the
desire for information to come from their physicians (66.7%) rather than fromother
staff (28.5%) or pamphlets (23.6%). Achieving a molecular response (as opposed to
hematologic/cytogenetic responses) generated the greatest satisfaction with their
physician (78.6%), medication (86.6%), outlook on life (85.7%), and day-to-day func-
tioning (85.7%). The percentage of patients rating their own health as excellent/
very good was 43.1% among those with a molecular response and 41.7% with a
cytogenetic response. However, 21.9% of all subjects rated their health as fair/poor.
CONCLUSIONS: Achievement of a molecular response was associated with a
higher satisfaction with a patient’s physician, medication, and outlook on life, as
well as an overall improvement in self-reported health ratings. Even in this highly
educated ACOR population, a need for physician-directed information about vari-
ous response criteria and counseling about the value of obtaining a molecular
response is desired.
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OBJECTIVES: To evaluate and compare the preferences for targeted therapy for
metastatic renal cell carcinoma in cancer patients, patients’ family members and
medical experts. METHODS: Using discrete choice experiment, survey questions
were constructed on the basis of six attributes of efficacy, adverse events and
administration. We designed two kinds of scenario sets as first-line therapy and
therapy for poor prognosis. A total of 485 individuals were completed question-
naire: 140 cancer patients, 60 patients’ familymembers and 285medical experts(39
oncology doctors, 34 oncology nurses, 133 nurses and 79 pharmacists).RESULTS: In
first-line therapy and therapy for poor prognosis, all six attributes in studies were
statistically significant so they were important for choices. In first-line therapy
coefficients of six attributes in patients and medical experts were all statistically
significant but not progression free survival(PFS) in patients’ family members. Be-
tween patients and doctors, PFS, hand-foot skin reaction(HFSR) and administration
were statistically significantly different. Between patients and nurses, the coeffi-
cients of bonemarrow suppression, HFSR, gastrointestinal perforation and admin-
istration were significantly different. In therapy for poor prognosis, six attributes
were statistically significant in patients but not administration in patients’ family
members, not HFSR, interstitial pneumonitis in doctors. Between patients and
doctors, coefficients of PFS, HFSR, asthenia and interstitial pneumonitis were dif-
ferent significantly. Between patients and nurses, five attributes were significantly
different except HFSR.CONCLUSIONS: Efficacy, adverse events and administration
were all important for preference in respondents. Comparisons of coefficients be-
tween subgroups represented different preferences of those groups. Medical ex-
perts especially doctors showed quite different preferences from patients and pa-
tients’ family members. Doctors considered efficacy more important than adverse
event so they favored the more effective and orally administered drug even if the
drug had adverse events more frequently. But patients and patients’ family mem-
bers showed reluctant attitudes about adverse events.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common cancers world-
wide. major treatment advances, however, have changed the assumptions about
A169V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
CRC; patients are now expected to survive longer and have the potential to expe-
rience various side effects related to chemotherapy. Knowing how patients value
the outcomes and preferences of treatment options for CRC is important to oncol-
ogists and policy makers in planning and introducing treatment interventions.
METHODS:Qualitative interviewswith 27 CRC patientswere used to identify seven
treatment attributes and their levels with regard to chemotherapy for CRC, for
inclusion in a discrete choice experiment (DCE) survey. These attributes were: life
expectancy, fatigue, diarrhoea, oral symptoms, hair loss, pain, and nausea and
vomiting. The survey was completed by 150 CRC patients to assess their prefer-
ences for the treatment of CRC. A conditional logit model was used to analyse the
data using STATA v9.0. RESULTS: The results of the DCE survey showed that, with
the exception of oral symptoms, all other attributes were found to be important
factors when it came to treatment decisions made by participants. The results
confirmed the prior hypothesis about the directions of attributes. For example, life
expectancy had a positive coefficient value, which indicated that the greater the
life expectancy, the more likely a participant would be to prefer that treatment. In
contrast, the negative values for pain, diarrhoea, fatigue, nausea and vomiting, and
hair loss indicate that participantswould not prefer a treatment that produce these
toxicities. Patients preferred to trade-off life expectancy for the reduction in the
likelihood of specific side effects. CONCLUSIONS: The results indicate the types of
risks and benefits that are important to patients with treatments for CRC. The
findings are likely to assist health care professionals in prioritising issues that need
to be discussed during treatment consultations.
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OBJECTIVES: This research study aimed to investigate the perception of cancer
patients towards the use of Traditional & Complementary Medicines (T&CM) for
cancer treatment. METHODS: Qualitative methodology was adapted to collect in-
depth information from consented cancer patients who were recruited from the
oncology wards at Penang General Hospital from May 2010 to August 2010. After
obtaining institutional ethical approval, patients with different types of cancer and
stages from the three major ethnic groups in Malaysia namely Malay, Chinese and
Indians were approached. Twenty semi-structured interviews were conducted af-
ter obtaining informed consent. All interviews were audiotaped, transcribed ver-
batim and translated into English for thematic content analysis. RESULTS: A total
of 3 themes were identified from the interview analysis: 1) positive attitude to-
wards spiritual ways of healing for cancer treatment, 2) concerns about the safety
and efficacy of T&CM for cancer treatment; and 3) concerns towards the legitimacy
of the claims made by traditional practitioners. Patients were willing to try non-
invasive treatments such as prayers, spiritual and faith healing therapies for can-
cer treatment. Lack of a fixed dosing system, unknown side effects and substan-
dard methods of preparation were other reported reasons for rejecting T&CM use.
The respondents showed a great concern towards the authenticity of claimsmade
by traditional practitioners and the majority demanded that true and fair claims
should be made by traditional practitioners in order to help patients in making
decisions regarding cancer therapy. CONCLUSIONS: The respondents in this study
did not appear to have attitudes regarding TCM that could lead to treatment delays
but thismay be due to the samplingmethod. Future studies are needed to evaluate
perceptions among thosewhohave defaulted treatment at any stage of cancer. The
current study has contributed to a greater understanding of the use of T&CM
among cancer patients that are not defaulting treatment.
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OBJECTIVES: New treatment improves efficacy and often has toxicities. The qual-
ity-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis in-
corporates survival, toxicities and quality of life into a single metric providing an
integrated measure of clinical benefit. Objective of this study was to use Q-TWiST
analysis comparing quality-adjusted survival between patients with chemo-re-
fractory wild-type KRAS metastatic colorectal cancer (mCRC) receiving panitu-
mumab  best supportive care (BSC) versus BSC alone. Because the trial design
allowed patients on BSc arm to receive panitumumab after disease progression,
whichmay have confounded overall survival (OS), the focus of this analysis was on
progression-free survival (PFS).METHODS: The time spent in the toxicity (grade 3
or 4 adverse events; TOX), time without symptoms of disease or toxicity (TWiST),
and relapse (after disease progression; REL) states were estimated, and adjusted
using utility weights derived from patient-reported EQ-5D measures. Quality-ad-
justed PFS was when the utility for REL was zero in the Q-TWiST analysis. Sensi-
tivity analyses were performed in which utility weights (varying from 0 to 1) were
applied to TOX and REL health states. RESULTS: The trial included 463 patients,
KRAS status ascertained in 427 (92%) of patients. Of these, 243 (57%) having wild-
type KRAS tumours (124 panitumumab BSC, 119 BSC alone) were included in the
analysis. Statistically significant difference between groups in quality-adjusted PFS
favoured panitumumab  BSC (12.3 weeks versus 5.8 weeks, respectively,
p0.0001). The difference continued to favour panitumumab  BSC for all hypo-
thetical utility weights applied to the TOX health state in sensitivity analyses.
Although OS was confounded by 76% of patients in the BSC alone arm receiving
panitumumab after disease progression, the difference in quality-adjusted OS was
also statistically significant and favoured panitumumab BSC. CONCLUSIONS: In
patients with chemo-refractory wild-type KRAS mCRC, panitumumab  BSC sig-
nificant improved quality-adjusted survival compared with BSC alone.
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OBJECTIVES: Our objective was to understand how oncologists view patient-re-
ported outcomes (PROs) and whether PRO data influences their clinical decision
making. METHODS: Twenty oncologists participated in 1 of 4 semi-structured fo-
cus groups (5 per group). Topics for discussion included: relative value of PROs
compared to other efficacy outcomes, impact of PROs on clinical decision making,
and interpretation of PRO data. Transcripts were analyzed using Atlas.ti software.
RESULTS: The oncologists represented a diverse sample in terms of gender (55%
male), years in practice (4-25), practice type/size, and tumor specialty. Most oncol-
ogists had no experience with PROs, but were able to identify several concepts
appropriate for PRO assessment (e.g., symptoms and functioning). All oncologists
agreed that when treating curable disease, clinical efficacy (overall survival, pro-
gression free survival) and toxicity were the main drivers of clinical decision mak-
ing. In the non-curative setting, all agreed that PRO data, particularly health-re-
lated quality of life data becomes paramount as a driver of treatment decision
making. Some oncologists felt that patient-reported symptoms were on a par with
toxicology, and saw a benefit to supplementing toxicity data with PRO data. All
agreed that patients were the best source of data regarding symptoms and that
many symptomswere consistent across tumor types. Concern over the subjectivity
and interpretability of PROs, however, was expressed and most oncologists stated
a preference for common toxicity criteria and performance status measures (e.g.,
Karnofsky). Most oncologists agreed that clear and concise reports of PRO datawith
clear explanations of the scale used and interpretability of change would increase
their likelihood of reviewing PRO data. CONCLUSIONS: Oncologists prioritize clin-
ical efficacy endpoints in their treatment decision making; however, in the non-
curative setting PRO data becomesmore influential. Improving the interpretability
of PROmeasures could increase the use of PRO data in treatment decisionmaking.
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OBJECTIVES: This study evaluated knowledge and attitude towards human papil-
loma virus (HPV) vaccination among women ages 18-24 years and examined pre-
dictors of attitude towards HPV vaccination. METHODS: A cross-sectional, self-
administered questionnaire was delivered to a convenience sample of female
University students in 2009. Questions on knowledge (9 items) and attitude (2
items) were measured using a 5-point Likert scale. The instrument also included
questions on demographics, HPV vaccination status, source of HPV-related infor-
mation, and healthcare professional’s recommendation. For the purpose of mod-
eling, knowledge (yes/no) and attitude (positive/negative) was reduced to a binary
variable. Data was coded and analyzed using SAS v9.2, by conducting descriptive
analyses, chi-square tests and logistic regression. RESULTS: A total of 136 subjects
completed the survey with a response rate of 46.5%. The mean age of the sample
was 20.67(1.78) years with the majority being unmarried (88.97%) and insured
(72.06%). HPV vaccination rate was 11%. Themean summary knowledge score was
4.4 (3.0) with a reliability coefficient of 0.7. Themean summary attitude scorewas
2.7 (1.2) with a reliability coefficient of 0.8. In the logistic regressionmodel, health
care professional’s recommendation to administer HPV vaccine was a significant
predictor of positive attitude towards the vaccine (OR2.886, 95% CI1.186-7.020,
p0.05) after controlling for race, education, age, knowledge, and vaccination
status. CONCLUSIONS: A healthcare professional’s recommendation to consider
the HPV vaccine was a significant predictor of attitude towards the vaccine. Sub-
optimal knowledge and negative attitude towards HPV vaccination underscore the
need for active education and accurate dissemination of information to women
regarding HPV vaccination.
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OBJECTIVES: Inform clinical trial designs with regards to Health Technology As-
sessment (HTA) agencies’ preferences regarding Quality of Life (QoL) measures for
prostate cancer. METHODS: We searched the Centre for Reviews and Dissemina-
tion database and HTA Watch® for any publication by an HTA agency on prostate
cancer and QoL using the search string “prostate cancer ANDQoL OR quality of life.
RESULTS:We identified 19 HTAs. Four HTAs evaluated drug treatments, 14 evalu-
ated procedures and one evaluated screening. The year of publication ranged from
1996 to 2007. UK agencies published eight of the HTAs, including the four evaluat-
ing drugs, a Norwegian agency published three, and agencies in France, Spain and
the US each published two, with the remaining HTA published by a German
agency. The results of the HTA review demonstrate a consensus regarding a lack of
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